Characteristics, treatments and 1‐year prognosis of hospitalized and ambulatory heart failure patients with chronic obstructive pulmonary disease in the European Society of Cardiology Heart Failure Long‐Term Registry

• Published in: European journal of heart failure 2018-01, Vol.20 (1), p.100-110
• Main Authors: Canepa, Marco, Straburzynska‐Migaj, Ewa, Drozdz, Jaroslaw, Fernandez‐Vivancos, Carla, Pinilla, Jose Manuel Garcia, Nyolczas, Noemi, Temporelli, Pier Luigi, Mebazaa, Alexandre, Lainscak, Mitja, Laroche, Cécile, Maggioni, Aldo Pietro, Piepoli, Massimo F., Coats, Andrew J.S., Ferrari, Roberto, Tavazzi, Luigi
• Format: Article
• Language: English
• Subjects: Beta‐blockers; Chronic obstructive pulmonary disease; Heart failure; Hospitalization; Mortality; Registry
• ISSN: 1388-9842; 1879-0844
• DOI: 10.1002/ejhf.964

Aims To describe the characteristics and assess the 1‐year outcomes of hospitalized (HHF) and chronic (CHF) heart failure patients with chronic obstructive pulmonary disease (COPD) enrolled in a large European registry between May 2011 and April 2013. Methods and results Overall, 1334/6920 (19.3%) HHF patients and 1322/9409 (14.1%) CHF patients were diagnosed with COPD. In both groups, patients with COPD were older, more frequently men, had a worse clinical presentation and a higher prevalence of co‐morbidities. In HHF, the increase in the use of heart failure (HF) medications at hospital discharge was greater in non‐COPD than in COPD for angiotensin‐converting enzyme inhibitors (+13.7% vs. +7.2%), beta‐blockers (+20.6% vs. +11.8%) and mineralocorticoid receptor antagonists (+20.9% vs. +17.3%), thus widening the gap in HF treatment already existing between the two groups at admission. In CHF patients, there was a similar increase in the use of these medications after enrollment visit in the two groups, leaving a significant difference of 8.2% for beta‐blockers in favour of non‐COPD patients (89.8% vs. 81.6%, P